Goldman Sachs
GNMX

Goldman Sachs’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Goldman Sachs’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-50,000
Closed -$67K – 6986
2017
Q2 		$67K Sell
50,000
-177,800
-78% -$257K ﹤0.01% 6284
2017
Q1 		$424K Buy
+227,800
New +$1.03M ﹤0.01% 5173

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs's GNMX Position: Q4 2018 in Review

Goldman Sachs sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2018, closing a stake of 30,960 shares — an estimated $38K sold.

Goldman Sachs first reported a position in GNMX in Q1 2015 and held it in 14 quarters. The position peaked at $524K in Q2 2017. 38 funds tracked by Wall St. Rank hold GNMX as of Q4 2018.

  • Goldman Sachs reported no remaining Aevi Genomic Medicine Inc position as of Q4 2018 after selling out during the quarter.
  • Goldman Sachs sold 30,960 Aevi Genomic Medicine Inc shares in Q4 2018, an estimated $38K.
  • Goldman Sachs first reported a position in Aevi Genomic Medicine Inc in Q1 2015 and held it in 14 quarters.
  • Goldman Sachs's Aevi Genomic Medicine Inc position peaked at $524K in Q2 2017.
  • 38 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2018.

Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.